Core Viewpoint - James River Group (JRVR) shares have increased by 6.5% recently, with a mean price target of $7.06 indicating a potential upside of 26.8% from the current price of $5.57 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $1.09, where the lowest estimate is $6.00 (7.7% increase) and the highest is $8.00 (43.6% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about JRVR's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which have increased by 10.5% over the past month [11][12] - The Zacks Consensus Estimate indicates that JRVR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as empirical research shows that they often mislead investors [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - nLight (LASR) shows potential for significant upside, with a mean price target of $39.83 indicating a 30.6% increase from the current price of $30.5 [1] Price Targets and Analyst Consensus - The average price target consists of six estimates ranging from $30.00 to $50.00, with a standard deviation of $6.34, indicating variability among analysts [2] - The lowest estimate suggests a decline of 1.6%, while the highest points to a 63.9% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about LASR's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 7.5% over the past month, with no negative revisions [12] - LASR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has shown a significant price increase of 22.2% over the past four weeks, with a mean price target of $23 indicating a potential upside of 161.4% from its current price of $8.8 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $16.00 to a high of $29.00, with a standard deviation of $4.93, indicating variability among analysts [2] - The lowest estimate suggests an increase of 81.8%, while the highest points to a 229.6% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding the price movement direction [9] Analyst Sentiment - Analysts are optimistic about DAWN's earnings prospects, as evidenced by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [11] - Over the last 30 days, six earnings estimates have been revised higher, resulting in an 18.2% increase in the Zacks Consensus Estimate [12] Zacks Rank - DAWN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful indication of the expected direction of price movement [14]

Core Viewpoint - Trimble Navigation (TRMB) shows potential for significant upside, with a mean price target of $98.11 indicating a 26.5% increase from its current price of $77.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $2.76, suggesting a consensus among analysts [2] - The lowest price target is $93.00, indicating a 19.9% increase, while the highest target is $102.00, suggesting a 31.5% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about TRMB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 5.2% over the past month, with six estimates revised upward and no negative revisions [12] - TRMB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][10] - Price targets can be influenced by business incentives, leading to overly optimistic estimates [8]

Group 1 - Fiverr International (FVRR) shares have increased by 1% over the past four weeks, closing at $22.33, with a mean price target of $31.9 indicating a potential upside of 42.9% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $4.98, where the lowest estimate is $25.00 (12% increase) and the highest is $44.00 (97% increase) [2] - Analysts show strong agreement on FVRR's ability to report better earnings, with a positive trend in earnings estimate revisions, which is a strong predictor of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for FVRR has increased by 20% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - FVRR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement, which is useful for further research [14]

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) shows potential for significant upside, with a mean price target of $11.1 indicating a 75.1% increase from its current price of $6.34 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.47, suggesting variability in analyst predictions. The lowest estimate is $6.58 (3.8% increase), while the highest is $14.00 (120.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EPRX's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two EPS estimates have increased while one has decreased, leading to a 16.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable measure of potential gains, it does provide a useful guide for price movement direction [14]

Core Viewpoint - The Pennant Group, Inc. (PNTG) shows potential for significant upside, with a mean price target of $33 indicating a 30.7% increase from the current price of $25.25 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.82, suggesting variability among analysts [2] - The lowest estimate is $28.00, indicating a 10.9% increase, while the highest estimate is $40.00, suggesting a 58.4% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about PNTG's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.6%, with two estimates moving higher and no negative revisions [12] - PNTG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Ategrity Specialty Insurance Company Holdings (ASIC) closed the last trading session at $18.29, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.8 indicates a 41.1% upside potential.The average comprises five short-term price targets ranging from a low of $23.00 to a high of $30.00, with a standard deviation of $2.95. While the lowest estimate indicates an increase ...

Core Viewpoint - Catalyst Pharmaceutical (CPRX) has shown a 7.2% increase in stock price over the past four weeks, with a mean price target of $34.5 indicating a potential upside of 51.5% from the current price of $22.78 [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $32.00 to a high of $40.00, with a standard deviation of $2.67, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a 40.5% increase, while the highest suggests a 75.6% upside, highlighting the variability in analyst predictions [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding CPRX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11] - Over the last 30 days, three earnings estimates have been revised upward, resulting in a 7.3% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Klaviyo, Inc. (KVYO) shares have increased by 20.7% in the past four weeks, closing at $29.49, with a potential upside of 47.5% based on Wall Street analysts' mean price target of $43.5 [1] Price Targets - The average of 20 short-term price targets ranges from a low of $30.00 to a high of $60.00, with a standard deviation of $5.88, indicating variability among analysts [2] - The lowest estimate suggests a 1.7% increase from the current price, while the highest estimate indicates a 103.5% upside [2] Analyst Sentiment - Analysts show strong agreement on KVYO's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with stock price movements, suggesting that upward revisions can indicate potential gains [11] Earnings Estimates - Over the last 30 days, seven earnings estimates for KVYO have been revised upward, with no negative revisions, leading to a Zacks Consensus Estimate increase of 191.7% [12] - KVYO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]